Press release
NASH Market Insight and Landscape report
Report Snapshot:NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their need for management. While awaiting the development of effective therapies, this disease warrants the attention of primary care physicians, specialists and health policy makers. Thelansis "NASH – Market Insight and Landscape report 2015 - 2030" report provides the detailed therapy area landscape of disease overview, pathogenesis, and country/region specific current treatment practice
The global non-alcoholic steatohepatitis (NASH) market is estimated ~$2,579 million in 2015, and is expected to cross $39,596 million by the end of 2030, growing at a CAGR of 21.9% from 2015 to 2030 (15 years of markets projections; four years of historical data, one year of current and eleven years of future market projections). North America, ASIA and Europe are the major region reported with a high prevalence & diagnosed patient pool, however US and Canada mutually contributed ~ 52.34 % of the total revenue followed by EU5(Germany, UK, France, Italy and Spain) with 23.67%. NASH is projected to be the leading cause of liver transplantation in the USA in the coming years which will increase overall disease burden within the space. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.
The disease segmentation of NASH patient pool further classified and segregated into different stages fibrosis (F0, F1, F2, F3 & F4-Cirrhosis) includes historical, current and projected epidemiology.
The overall market for NASH has been defined on the basis of country-specific current clinical practice includes symptomatic and off-label therapies, patient share and disease burden (treatment cost, compliance, and market access) has been translated into market.
Emerging therapies:
The developmental pathway for therapeutic agents involves navigating multiple complexities that include the non-linear, heterogeneous nature of disease progression, and the limitations in identifying clinically relevant outcomes. The design of each phase of a clinical trial for a potential therapeutic agent is strongly influenced by the drug’s mechanism of action, characteristics of the patient population (F0, F1, F2, F3 & F4-Cirrhosis) influence by trial design. Currently there are multiple players involved in the designing and development of novel therapies such as: Elafibranor (GFT505) : Genfit, Obeticholic Acid (OCA): Intercept Pharmaceuticals, Cenicriviroc (CVC): (Allergan- Tobira), GS-9674, GS-0976: Gilead Sciences, BMS-98603: BMS, MSDC-0602K: Cirius Therapeutics, Emricasan (IDN-6556): Conatus Pharmaceuticals, NGM282: NGM Biopharmaceuticals, IMM-124E : Immuron, Selonsertib: Gilead Sciences, Aramchol_005: Galmed, GR-MD-02: Galectin Therapeutics
Annual cost of therapy:
Due to lack of treatment options, advanced liver diseases associated with NAFLD will be doubles over coming years. Direct healthcare costs in the USA the annual cost of care per NASH patient with private/ public insurance ranges between USD 3, 367 to USD 8,750 considering current treatment options. These costs are significantly higher in case of patients with control other metabolic comorbidities conditions. The European nations majorly EU5 countries are having the cost burden in similar line, however the reference pricing system and generic entry plays a role in controlling the cost burden
http://www.thelansis.com
Contact Person: Prasoon Narang
Contact NO.:+1-13023803552
Thelansis Knowledge Partners
183 Asylum Street Hartfort
CT-06103, US
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release NASH Market Insight and Landscape report here
News-ID: 1726497 • Views: …
More Releases from Thelansis Knowledge Partners

Autoimmune Hepatitis (AIH) – Market outlook, Epidemiology, Market Forecast and …
Autoimmune hepatitis (AIH) is a non-contagious, chronic, inflammatory, autoimmune disease in which one’s own immune system attacks healthy, normal liver cells.
Etiology-
The exact cause of autoimmune hepatitis is unknown. It is believed to be due to a combination of environmental, genetic, and immunologic factors.
Classification-
There are two clinically relevant types of AIH, including type 1and type 2.
Type 1- also referred to as the classic type, is typically diagnosed in adulthood
Type 2…

Charcot–Marie–Tooth_Market Outlook and Competitive Landscape Report 2018 – …
Report Overview
The report provides a comprehensive view of disease events, types, severity, progression, symptoms, risk factors, pathogenesis and treatment guidelines at country level
Comprehensive insight on patient segmentation has been provided into the epidemiology of the Charcot–Marie–Tooth (CMT) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
Drug utilization and analysis on the current clinical practice,…

Pulmonary Arterial Hypertension (PAH) - Market Outlook and Competitive Landscape …
Report Overview
The report provides a comprehensive view of disease events, types, severity, progression, symptoms, risk factors, pathogenesis and treatment guidelines at country level
Comprehensive insight on patient segmentation has been provided into the epidemiology of the Pulmonary Arterial Hypertension (PAH) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
Drug utilization and analysis on the current…

Thelansis "Crohn’s disease (CD) – Market Outlook and Competitive Landscape r …
Report Snapshot:
Crohn’s disease (CD) is a chronic disorder characterized by exacerbations and periods of remission that cause inflammation of the gastrointestinal (GI) tract. Although it can involve any area of the GI tract, it most commonly affects the small intestine and/or colon. Crohn’s disease and ulcerative colitis are the two main diseases among a group of illnesses called inflammatory bowel disease (IBD). The symptoms of these two…
More Releases for NASH
IQ4I Research published “Non-alcoholic steatohepataitis (NASH) Pipeline Analys …
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report…
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market…
OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026
First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
Leah Nash new photographer at Gruppe28
Gruppe28 is pleased to announce that Leah Nash joined its international network of high quality photographers. She will be presented exclusively and internationally by the photo agency Gruppe28 based in Hamburg, Germany. Leah Nash is an award winning, Portland-based photographer with a passion for documenting the everyday and the extreme, which she often finds are one and the same. Her work was published in distinguished magazines and newspapers including Mother…